Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer

Cancer Research

Volumn 65, Issue 2, 2005, Pages 387-393

  Han, Gui Zhen ^a   Liu, Zhi Jian ^a   Shimoi, Kayoko ^b   Bao, Ting Zhu ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MITOMYCIN C; NAVELBINE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CULTURE; CELL STRAIN MCF 7; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DOSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MICROTUBULE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; ESTRADIOL; FEMALE; FLUOROURACIL; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 12544253612     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: Review and perspectives. Carcinogenesis 1998;19:1-27.
2. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998;58:2269-77.
3. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-6.
4. Cushman M, He HM, Katzenellenbogen JA, et al. Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. J Med Chem 1997;40:2323-34.
5. Cushman M, He HM, Katzenellenbogan JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 1995;38:2041-9.
6. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 1994;368:237-9.
7. Liu ZJ, Zhu BT. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J Steroid Biochem Mol Biol 2004;88:265-75.
8. Pribluda VS, Gubish ER, Lavallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 2000;19:173-9.
9. Lottering M-L, Haag M, Seegers JC. Effects of 17β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 1992;52:5926-32.
10. Lottering ML, Haag M, Seegers JC. Effects of 17β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 1992;52:5926-32.
11. Seegers JC, Aveling ML, van Aswegen CH, Cross M, Kock F, Joubert WS. The cytotoxic effects of estradiol-17β catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J Steroid Biochem 1989;32:797-809.
12. Gillies RJ, Diclier N, Denton M. Determination of cell number in monolayer culture. Anal Biochem 1986;159:109-13.
13. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann Rev Med 1997;48:353-74.
14. Abal M, Andreu JM, Barasoain I. Taxanes: Microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3:193-203.
15. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
16. Gregory RK, Smith IE. Vinorelbinē-a clinical review. Br J Cancer 2000;82:1907-13.
17. Glaxo Wellcome. Navelbine product monograph. Mississauga, Ontario (Canada): Glaxo Wellcome; October 29, 1998.
18. Vinorelbine. USP DI. Volume 1. Drug information for the health care professional. Update monographs. Englewood (CO): Micromedex, Inc.; August 9, 2000.
19. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72.